COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Phase 2a Study of AdV-tk With Standard Radiation Therapy for Malignant Glioma (BrTK02) (BrTK02)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00589875
Recruitment Status : Completed
First Posted : January 10, 2008
Last Update Posted : April 11, 2017
Information provided by (Responsible Party):
Advantagene, Inc. d.b.a. Candel Therapeutics